Blog

FSR Objects to Florida Board of Pharmacy’s Collaborative Practice Certification

The Florida Board of Pharmacy Joint Rules Committee proposed a new rule last month that would expand the role pharmacists have in treating patients with chronic conditions. The Florida Society of Rheumatology (FSR) opposed aspects of the rule, and submitted comments that objected to some of the listed chronic conditions within the agreement.

The Florida Board of Pharmacy Joint Rules Committee proposed a new rule last month that would expand the role pharmacists have in treating patients with chronic conditions. The Florida Society of Rheumatology (FSR) opposed aspects of the rule, and submitted comments that objected to some of the listed chronic conditions within the agreement.

The proposed rule-making follows from the passage of HB 389 this Spring, which expanded pharmacist scope of practice when a Collaborative Pharmacy Practice Agreement is in place with a collaborating physician.

The proposal would authorize pharmacists with such an agreement to provide specified patient care services to the collaborating physician's patients for the treatment of hyperlipidemia, hypertension, anti-coagulation management, smoking cessation, osteoporosis, osteoarthritis, opioid use disorder, and any disease expected to last greater one year and requiring ongoing medical treatment and drug therapy. In addition, pharmacists with an agreement would be authorized to treat conditions enumerated in 465.1865 of the Florida Statutes.

FSR was deeply concerned about certain aspects of the board's proposal, and requested removal of the language allowing pharmacists to treat any ongoing chronic conditions and osteoporosis. FSR argued that the ability to treat any chronic condition was too broad and too vague to ensure pharmacist treatment remained within the bounds of a collaborative practice agreement. In addition, FSR argued that the complexity of treatment decisions for osteoporosis patients warranted the attention of a physician. 

In a positive step, the Board of Pharmacy has provisionally concurred with FSR's comments Language allowing treatment of any chronic condition and osteoporosis was deleted from the latest draft released prior to the Board's next meeting scheduled for July 29th. 

FSR will continue its advocacy throughout the rule-making process to ensure that the expansion of scope of practice for pharmacists does not impede safety and excellence in care for patients treated by FSR's members.

Read the Full Comment

Archive

Contributors

    Archive

    Contributors